MindBio Therapeutics (CVE:MBIO) | WebDisclosure

Basculer en Français

10161	Companies
208730	Keywords
138855	Articles
110646	Press releases

Home
Companies
MindBio Therapeutics

PRESS RELEASE

published on 03/20/2024 at 09:50, 2 years ago

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
Phase 2B trial begins with MB22001 for Major Depressive Disorder patients. Successful Phase 2A trial showed 53% in remission with 14.1 MADRS score drop. MindBio aims to scale up psychedelic treatment for depression

MB22001 Major Depressive Disorder Phase 2b MindBio Psychedelic Treatment
PRESS RELEASE

published on 03/20/2024 at 09:50, 2 years ago

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
MindBio Therapeutics Corp. commences Phase 2B clinical trial for MB22001 in Major Depressive Disorder patients, following successful Phase 2A trial with significant results

Psychedelic Medicine MindBio Therapeutics Corp. MB22001 Major Depressive Disorder Clinical Trial
BRIEF

published on 03/04/2024 at 11:05, 2 years ago

MindBio Therapeutics passe à l'essai de phase 2B pour la médecine psychédélique dans le trouble dépressif majeur

MindBio Thérapeutique Trouble Dépressif Majeur Essai Clinique De Phase 2B Médecine Psychédélique Microdosage Du LSD
BRIEF

published on 03/04/2024 at 11:05, 2 years ago

MindBio Therapeutics Advances to Phase 2B Trial for Psychedelic Medicine in Major Depressive Disorder

Psychedelic Medicine Major Depressive Disorder Microdosing LSD Phase 2b Clinical Trial MindBio Therapeutics
PRESS RELEASE

published on 03/04/2024 at 11:00, 2 years ago

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
Ethics and regulatory approvals finalized for world-first take-home use of psychedelic medicine MB22001 in Phase 2B randomized controlled trial for Major Depressive Disorder by MindBio Therapeutics Corp

Psychedelic Medicine MB22001 Major Depressive Disorder MindBio Therapeutics Phase 2B Trial
BRIEF

published on 02/26/2024 at 10:30, 2 years 1 month ago

MindBio annonce des résultats positifs dans un essai clinique de microdosage à domicile pour la dépression

Depression MB22001 Essai Clinique MindBio Microdosage
BRIEF

published on 02/26/2024 at 10:30, 2 years 1 month ago

MindBio Announces Positive Results in At-Home Microdosing Clinical Trial for Depression

Depression MB22001 MindBio Microdosing Clinical Test
PRESS RELEASE

published on 02/26/2024 at 10:30, 2 years 1 month ago

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
MindBio announces positive top line data from its world-first take-home microdosing depression clinical trial using MB22001. Patients experienced a 60% reduction in depressive symptoms with an impressive mean 14.1 point drop in MADRS score over 8 weeks

Psychedelic Medicine Depression MB22001 Clinical Trial MindBio
PRESS RELEASE

published on 02/14/2024 at 10:00, 2 years 1 month ago

MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
MindBio Therapeutics Corp. completes landmark Phase 2a clinical trial in Major Depressive Disorder patients with regulatory approvals for take-home use of proprietary microdose LSD MB22001. Phase 2B trial in late-stage cancer patients ongoing. CEO Justin Hanka announces pivotal moment for psychiatric medicine development

MindBio Therapeutics Corp. Major Depressive Disorder Clinical Trial Phase 2a LSD Microdosing
PRESS RELEASE

published on 01/30/2024 at 08:10, 2 years 2 months ago

MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients
MindBio Therapeutics Corp. is nearing completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. The company expects top line results to be announced in March 2024. MindBio is conducting trials with regulatory approvals for take-home use of a special form of LSD in microdoses, aiming to treat mental health conditions

MindBio Therapeutics Corp. Phase 2a Clinical Trial MB22001 Major Depressive Disorder Microdosing LSD

Accesswire

Published on 04/02/2026 at 22:00, 23 hours 25 minutes ago

Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Published on 04/02/2026 at 18:32, 1 day 2 hours ago

Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 1 day 6 hours ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Published on 04/02/2026 at 14:40, 1 day 6 hours ago

Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Published on 04/02/2026 at 14:30, 1 day 6 hours ago

Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution

View all ACCESSWIRE

EQS Group

Published on 04/03/2026 at 18:00, 3 hours 25 minutes ago

IEVA GROUP: IMPLEMENTATION OF A LIQUIDITY AGREEMENT WITH CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 18:00, 3 hours 25 minutes ago

IEVA GROUP: MISE EN OEUVRE D’UN CONTRAT DE LIQUIDITE AVEC LE CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 17:45, 3 hours 40 minutes ago

Atbash Launches on Chromia to Enable Verifiable, User-Controlled AI Systems
Published on 04/03/2026 at 17:40, 3 hours 45 minutes ago

BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.04.26.
Published on 04/03/2026 at 17:05, 4 hours 20 minutes ago

At WMF a new edition of AI Global Summit, an international reference point on Artificial Intelligence

Les Echos

Published on 04/03/2026 at 18:46, 2 hours 38 minutes ago

Disclosure of Share Capital and Voting Rights as of March 31, 2026
Published on 04/03/2026 at 18:46, 2 hours 38 minutes ago

Déclaration du nombre d’actions et droits de vote au 31 mars 2026
Published on 04/03/2026 at 18:01, 3 hours 23 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 3 hours 25 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 3 hours 25 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 mars 2026

View all LES ECHOS COMFI WIRE